{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T17:08:35Z","timestamp":1775668115036,"version":"3.50.1"},"reference-count":38,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2022.11520","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T11:05:22Z","timestamp":1658228722000},"source":"Crossref","is-referenced-by-count":9,"title":["Management of a rare ovarian carcinosarcoma: A case report and literature review"],"prefix":"10.3892","volume":"24","author":[{"given":"Jun","family":"Fu","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, Ningbo Women and Children's Hospital, Haishu, Ningbo, Zhejiang 315012, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"key20220825121534_b1-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ygyno.2011.12.418","article-title":"Carcinosarcoma of the ovary: A review of the literature","volume":"125","author":"del Carmen","year":"2012","journal-title":"Gynecol Oncol"},{"key":"key20220825121534_b2-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1006\/gyno.1997.4625","article-title":"Malignant mixed mesodermal ovarian tumor treatment and prognosis: A 20-year experience","volume":"65","author":"Le","year":"1997","journal-title":"Gynecol Oncol"},{"key":"key20220825121534_b3-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/PGP.0000000000000645","article-title":"Mutational and immunophenotypic profiling of a series of 8 Tubo-ovarian carcinosarcomas revealed a monoclonal origin of the disease","volume":"39","author":"Trento","year":"2020","journal-title":"Int J Gynecol Pathol"},{"key":"key20220825121534_b4-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ygyno.2004.02.016","article-title":"Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT)","volume":"93","author":"Barnholtz-Sloan","year":"2004","journal-title":"Gynecol Oncol"},{"key":"key20220825121534_b5-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00432-020-03234-6","article-title":"Paclitaxel and platinum chemotherapy for malignant mixed m\u00fcllerian tumors of the ovary","volume":"85","author":"Duska","year":"2002","journal-title":"Gynecol Oncol"},{"key":"key20220825121534_b6-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.3892\/mmr.2018.8467","article-title":"Application of antibodies against Borna disease virus phosphoprotein and nucleoprotein on paraffin sections","volume":"17","author":"Huang","year":"2018","journal-title":"Mol Med Rep"},{"key":"key20220825121534_b7-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/cyt.12156","article-title":"Optimization of immunocytochemistry in cytology: comparison of two protocols for fixation and preservation on cytospin and smear preparations","volume":"26","author":"Pinheiro","year":"2015","journal-title":"Cytopathology"},{"key":"key20220825121534_b8-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.ygyno.2020.09.029","article-title":"Clinical assays for assessment of homologous recombination DNA repair deficiency","volume":"159","author":"Stover","year":"2020","journal-title":"Gynecol Oncol"},{"key":"key20220825121534_b9-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/BF01218365","article-title":"The use of the Calvert formula to determine the optimal carboplatin dosage","volume":"121","author":"van Warmerdam","year":"1995","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20220825121534_b10-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1007\/s13224-015-0788-4","article-title":"A rare tumor of the ovary: carcinosarcoma report and review of literature","volume":"66","author":"Pankaj","year":"2016","journal-title":"J Obstet Gynaecol India"},{"key":"key20220825121534_b11-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1046\/j.1525-1438.2002.01069.x","article-title":"Rhabdomyosarcoma of the uterus: report of two cases, including one of the spindle cell variant","volume":"12","author":"McCluggage","year":"2002","journal-title":"Int J Gynecol Cancer"},{"key":"key20220825121534_b12-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/uog.23733","article-title":"Imaging in gynecological disease: clinical and ultrasound characteristics of ovarian carcinosarcomas","volume":"59","author":"Ciccarone","year":"2022","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key20220825121534_b13-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s11604-020-01072-7","article-title":"Carcinosarcoma of the ovary: MR and clinical findings compared with high-grade serous carcinoma","volume":"39","author":"Saida","year":"2021","journal-title":"Jpn J Radiol"},{"issue":"1022","key":"key20220825121534_b14-ETM-24-3-11520","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.147390","article-title":"Carcinosarcoma of ovary with its various immunohistochemical expression: Report of a rare case","volume":"11","author":"Dasgupta","year":"2015","journal-title":"J Cancer Res Ther"},{"key":"key20220825121534_b15-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/PGP.0000000000000290","article-title":"Two cases of carcinosarcomas of the ovary involved in hereditary cancer syndromes","volume":"36","author":"Carnevali","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"key20220825121534_b16-ETM-24-3-11520","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1738::AID-CNCR21>3.0.CO;2-4","article-title":"Primary ovarian sarcoma: Analysis of prognostic variables and the role of surgical cytoreduction","volume":"82","author":"Sood","year":"1998","journal-title":"Cancer"},{"issue":"106","key":"key20220825121534_b17-ETM-24-3-11520","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-30-106","article-title":"Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody","volume":"30","author":"Raji","year":"2011","journal-title":"J Exp Clin Cancer Res"},{"issue":"e0170879","key":"key20220825121534_b18-ETM-24-3-11520","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170879","article-title":"Clinical significance of programmed death Ligand-1 and intra-tumoral CD8+ T lymphocytes in ovarian carcinosarcoma","volume":"12","author":"Zhu","year":"2017","journal-title":"PLoS One"},{"key":"key20220825121534_b19-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ygyno.2016.04.025","article-title":"Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A national cancer database analysis","volume":"142","author":"Rauh-Hain","year":"2016","journal-title":"Gynecol Oncol"},{"key":"key20220825121534_b20-ETM-24-3-11520","first-page":"1003","article-title":"A population-based series of ovarian carcinosarcomas with long-term follow-up","volume":"33","author":"Paulsson","year":"2013","journal-title":"Anticancer Res"},{"key":"key20220825121534_b21-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1046\/j.1365-2559.2000.01015.x","article-title":"Prognostic factors in ovarian carcinosarcoma: A clinicopathological and immunohistochemical analysis of 23 cases","volume":"37","author":"Ariyoshi","year":"2000","journal-title":"Histopathology"},{"key":"key20220825121534_b22-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ygyno.2004.09.051","article-title":"Clinicopathological features of ovarian carcinosarcomas: A single institution experience","volume":"96","author":"Zorzou","year":"2005","journal-title":"Gynecol Oncol"},{"key":"key20220825121534_b23-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ygyno.2014.03.002","article-title":"Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma","volume":"133","author":"Doo","year":"2014","journal-title":"Gynecol Oncol"},{"key":"key20220825121534_b24-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1002\/cncr.20256","article-title":"Carcinosarcoma of the ovary: 19 years of prospective data from a single center","volume":"100","author":"Brown","year":"2004","journal-title":"Cancer"},{"key":"key20220825121534_b25-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.2147\/CMAR.S166524","article-title":"Prognostic significance of lymph node metastasis and lymphadenectomy in early-stage ovarian carcinosarcoma","volume":"10","author":"Wang","year":"2018","journal-title":"Cancer Manag Res"},{"key":"key20220825121534_b26-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","article-title":"Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Armstrong","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"key20220825121534_b27-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ygyno.2005.07.119","article-title":"Carcinosarcoma of the ovary-a case series","volume":"100","author":"Rutledge","year":"2006","journal-title":"Gynecol Oncol"},{"key":"key20220825121534_b28-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1525-1438.2007.00948.x","article-title":"Carcinosarcoma of the ovary","volume":"18","author":"Silasi","year":"2008","journal-title":"Int J Gynecol Cancer"},{"issue":"172","key":"key20220825121534_b29-ETM-24-3-11520","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4082-6","article-title":"Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: A single institution case series and review of the literature","volume":"18","author":"Brackmann","year":"2018","journal-title":"BMC Cancer"},{"key":"key20220825121534_b30-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ygyno.2004.01.007","article-title":"Cisplatin as initial chemotherapy in ovarian carcinosarcomas: A gynecologic oncology group study","volume":"93","author":"Tate Thigpen","year":"2004","journal-title":"Gynecol Oncol"},{"key":"key20220825121534_b31-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/1097-0142(19951001)76:7<1209::aid-cncr2820760717>3.0.co;2-v","article-title":"Malignant mixed m\u00fcllerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy","volume":"76","author":"Muntz","year":"1995","journal-title":"Cancer"},{"key":"key20220825121534_b32-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ygyno.2013.06.034","article-title":"Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome","volume":"131","author":"George","year":"2013","journal-title":"Gynecol Oncol"},{"key":"key20220825121534_b33-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1097\/IGC.0000000000000228","article-title":"Gynecologic cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma","volume":"24 (9 Suppl 3)","author":"Berton-Rigaud","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"e389","key":"key20220825121534_b34-ETM-24-3-11520","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.389","article-title":"The use of lattice radiation therapy (LRT) in the treatment of bulky tumors: A case report of a large metastatic mixed mullerian ovarian tumor","volume":"7","author":"Blanco Suarez","year":"2015","journal-title":"Cureus"},{"key":"key20220825121534_b35-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/PGP.0b013e31823bb24d","article-title":"HER2\/neu as a potential target for immunotherapy in gynecologic carcinosarcomas","volume":"31","author":"Guzzo","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"key20220825121534_b36-ETM-24-3-11520","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.1158\/1078-0432.CCR-16-2862","article-title":"SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2\/Neu expression","volume":"23","author":"Menderes","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"123","key":"key20220825121534_b37-ETM-24-3-11520","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-015-0241-7","article-title":"Solitomab, an EpCAM\/CD3 bispecific antibody construct (BiTE\u00ae), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro","volume":"34","author":"Ferrari","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"issue":"253","key":"key20220825121534_b38-ETM-24-3-11520","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-253","article-title":"Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway","volume":"9","author":"Cubas","year":"2010","journal-title":"Mol Cancer"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T09:23:24Z","timestamp":1661419404000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2022.11520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,7,19]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2022.11520","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]},"article-number":"583"}}